Evidence map›Paper›PMID 41244339›Full record

ReviewBioengineering & translational medicine2025

Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review.

Wenyu Fu, Ruier Xue, Mohit N Shivdasani, Yanfang Wu, Dongfei Chen, Tianruo Guo, Nigel H Lovell, Ewa M Goldys, Tingxiu Xiang, Yanan Huang and 1 more

Abstract readReview
In one paragraph

Review in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenyu FuGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Ruier XueGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Mohit N ShivdasaniGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Yanfang WuDepartment of Chemistry University of Otago Dunedin New Zealand.
Dongfei ChenGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Tianruo GuoGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Nigel H LovellGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Ewa M GoldysGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Tingxiu XiangChongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis Chongqing University Cancer Hospital Chongqing China.
Yanan HuangGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.
Fei DengGraduate School of Biomedical Engineering UNSW Sydney Sydney New South Wales Australia.ORCID https://orcid.org/0000-0002-5606-0278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) encompasses a group of intestinal disorders, primarily Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the digestive tract. Despite extensive research, the etiology of IBD remains largely unknown, and its progression and prognosis are unpredictable, often involving uncontrolled disease behavior. Current diagnostic and monitoring techniques, such as endoscopy, scoring systems, computed tomography, and ultrasound, provide valuable tools for assessing and monitoring disease progression; but are often used in conjunction with biomarker testing to achieve rapid and accurate results. Recent advances in biosensors, which integrate biorecognition elements with signal transduction platforms, offer immense potential to improve IBD diagnostics by enabling real-time, precise, and non-invasive detection of biomarkers such as C-reactive protein, calprotectin, and cytokines. This review examines existing IBD diagnostic techniques, their limitations, and the emerging role of biosensors in addressing these challenges. It explores the development of electrochemical and optical biosensors, highlights the key biomarkers utilized in these technologies, and identifies challenges and future opportunities for advancing next-generation biosensors for IBD diagnostics and monitoring. These innovations hold promise for enhancing IBD diagnosis, monitoring, and personalized disease management.

Indexed as

biomarkerbiosensorsdiagnosisinflammatory bowel disease

Identifiers

PMID41244339
PMCPMC12617555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.